LAM561 (idroxioleic acid/2-OHOA)

About Laminar Pharmaceuticals

Laminar Pharmaceuticals, founded in 2006 as a spin-off from the University of the Balearic Islands, is developing a novel class of drugs based on its proprietary Membrane Lipid Therapy (MELItherapy) platform. Its lead asset, LAM561 (idroxioleic acid/2-hydroxyoleic acid), is in a pivotal Phase 2b/3 trial (CLINGLIO) for newly diagnosed glioblastoma, with other programs targeting neurodegenerative and rare diseases. The company is privately held, pre-revenue, and is currently seeking a new capital round to advance its clinical pipeline.

Therapeutic Areas

Other Newly Diagnosed Glioblastoma Drugs